Home / Stocks / VTRS

Viatris (VTRS, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Viatris (VTRS, Pharmaceuticals) trades at a blended P/E of 6.6, about 29% below its historical normal valuation, with a forward growth estimate of 7.8% and a PEG of 0.85. Analysts' one-year estimates have been hit 45% of the time.

DATA AS OF 2026-08-21
Blended P/E
6.6
Normal P/E
9.3
PEG
0.85
Fwd growth
7.8%
Div yield
3.0%
RSI (14)
44.1
Neutral

The Street vs SeerForecast

Wall Street's mean price target for VTRS is $18.50 across 8 analysts, 13.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

Price and rating by weekClose moved +4.3 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Fairly valued, close 15.56 (recalculated)2026-06-10: Fairly valued, close 15.77 (recalculated)2026-06-14: Fairly valued, close 16.48 (recalculated)2026-06-16: Fairly valued, close 16.04 (recalculated)2026-06-21: Fairly valued, close 15.37 (recalculated)2026-07-02: Fairly valued, close 16.70 (recalculated)2026-07-06: Fairly valued, close 16.80 (recalculated)2026-07-09: Fairly valued, close 16.34 (recalculated)2026-07-12: Fairly valued, close 16.27 (recalculated)2026-07-13: Fairly valued, close 16.39 (recalculated)2026-07-14: Fairly valued, close 16.31 (recalculated)2026-07-20: Fairly valued, close 16.99 (recalculated)2026-07-22: Fairly valued, close 17.01 (recalculated)2026-07-25: Fairly valued, close 17.24 (recalculated)2026-07-27: Fairly valued, close 17.64 (recalculated)2026-07-31: Fairly valued, close 17.56 (recalculated)2026-08-03: Fairly valued, close 17.562026-08-07: Fairly valued, close 16.43 (recalculated)2026-08-10: Fairly valued, close 16.432026-08-14: Fairly valued, close 16.23 (recalculated)2026-08-17: Fairly valued, close 16.2316162026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 6.7-28%Fairly valued
2026-06-10P/E 6.6-29%Fairly valued
2026-06-14P/E 6.6-29%Fairly valued
2026-06-16P/E 6.6-29%Fairly valued
2026-06-21P/E 6.6-29%Fairly valued
2026-07-02P/E 6.7-28%Fairly valued
2026-07-06P/E 6.9-26%Fairly valued
2026-07-09P/E 6.9-26%Fairly valued
2026-07-12P/E 6.8-28%Fairly valued
2026-07-13P/E 6.8-28%Fairly valued
2026-07-14P/E 6.8-28%Fairly valued
2026-07-20P/E 7.2-23%Fairly valued
2026-07-22P/E 7.2-23%Fairly valued
2026-07-25P/E 7.2-23%Fairly valued
2026-07-27P/E 7.2-23%Fairly valued
2026-07-31P/E 7.4-21%Fairly valued
2026-08-03P/E 7.3-22%Fairly valued
2026-08-07P/E 6.7-28%Fairly valued
2026-08-10P/E 6.8-27%Fairly valued
2026-08-14P/E 6.6-29%Fairly valued
2026-08-17P/E 6.7-29%Fairly valued
2026-08-21P/E 6.6-29%Fairly valued ← now

Frequently asked questions

Is Viatris stock overvalued?

At a blended P/E of 6.6 versus its historical normal P/E of 9.3, Viatris trades about 29% below its typical valuation, with a PEG of 0.85 on 7.8% forward growth. tickerseer currently rates it fairly valued.

What is Viatris's fair value and PEG?

Viatris trades at a blended P/E of 6.6 against a historical normal P/E of 9.3, a PEG of 0.85, and a forward growth estimate of 7.8%.

Has tickerseer's rating of Viatris changed?

tickerseer's rating has been fairly valued since 2026-06-03.

What is the analyst price target for Viatris?

The mean Wall Street price target for Viatris is $18.50 across 8 analysts, 13.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track VTRS free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.